Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen | Zendy

Tahani Bin Ali | Zendy; Maryam Behfar | Zendy; Rashin Mohseni | Zendy; Pourya Salajegheh | Zendy; Maged Kheder | Zendy; Faihaa Hkima Abou Fakher | Zendy; Zeynab Nikfetrat | Zendy; Fahimeh Jafari | Zendy; Parisa Naji | Zendy; Amir Ali Hamidieh | Zendy

Open Access

Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen

Author(s) -

Tahani Bin Ali,

Maryam Behfar,

Rashin Mohseni,

Pourya Salajegheh,

Maged Kheder,

Faihaa Hkima Abou Fakher,

Zeynab Nikfetrat,

Fahimeh Jafari,

Parisa Naji,

Amir Ali Hamidieh

Publication year - 2021

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2021.06.002

Subject(s) - medicine , regimen , hematopoietic stem cell transplantation , adverse effect , donor lymphocyte infusion , transplantation , graft versus host disease , gastroenterology , lymphocyte , surgery

Mixed chimerism is a major concern after allogenic hematopoietic stem cell transplantation (HSCT) using a reduced-intensity conditioning (RIC) regimen in primary immunodeficiencies (PIDs). A donor lymphocyte infusion (DLI) escalating dose regimen has been developed with the aim of reducing toxicity while preserving efficacy. However, the graft-versus-host disease (GvHD) development remains the most common and adverse effect of DLI and continues to be a limiting factor in its application, especially nonmalignant diseases such as PIDs. We prospectively evaluated PID patients after HSCT using RIC in Childrens Medical Center, who were candidates for an escalating dose of DLI for MC from 2016 to 2018.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research